Introduction {#section1-1849454418763725}
============

Most follicular thyroid carcinomas (FTCs) grow slowly after they are first identified at an early stage. It is frequently cured with adequate surgical management and radioactive iodine ablation therapy. However, few cases develop fast with lung and bone metastases. Most metastatic FTCs are unresectable and refractory to radioactive iodine and associated with poor survival.^[@bibr1-1849454418763725]^ Analysis of carcinogenesis has revealed that gene mutations play a very important role in the progression and development of tumors. The genetic profile of solid tumors is often obtained from surgical or biopsy specimens. However, tumor samples may not be obtained due to the confirmation of metastasis. In that situation, blood samples or biopsy can be used for analysis. Several studies of circulating cell-free DNA (cfDNA) in plasma have been used for analyzing individual loci, genes, or structural variants to quantify tumor burden and detect previously characterized resistance-conferring mutations.^[@bibr2-1849454418763725][@bibr3-1849454418763725]--[@bibr4-1849454418763725]^ Individual mutations of cfDNA and SLC5A8 and SLC26A4 hypermethylation of thyroid carcinoma including follicular carcinoma have been reported.^[@bibr5-1849454418763725]^ Given that sequencing of entire genes to detect FTC mutations in circulating DNA has not been demonstrated, we report a somatic mutational analysis of cfDNA in a FTC patient with lung and bone metastases by whole exome sequencing (WES).

The results demonstrate that the detection of cfDNA may reflect the mutation of FTC and further develop to be a better way for monitoring the progression of thyroid cancer.

Patient and methods {#section2-1849454418763725}
===================

Patient {#section3-1849454418763725}
-------

A 55-year-old woman was diagnosed with FTC with synchronous bone and lung metastases and then performed total thyroidectomy at Shanghai Jiao Tong University Affiliated Sixth People's Hospital ([Figure 1](#fig1-1849454418763725){ref-type="fig"}). The informed consent for DNA sequencing was obtained from the patient. Preoperative peripheral cell-free plasma and peripheral blood leukocytes and postoperative formalin-fixed, paraffin-embedded (FFPE) thyroid tumor of this patient were obtained. Procedure and protocol were reviewed and approved by the ethics committee of the Sixth People's Hospital.

![Imaging of primary and metastasis lesions and pathological examination of primary thyroid lesion. (a) Imaging CT of primary thyroid lesion. Black arrow indicates tumor location. (b) Histological analysis of primary lesion of FTC (×100). (c) Lung metastasis as indicated by white arrow. (d) Rib metastasis as indicated by black arrow. CT: computed tomography; FTC: follicular thyroid carcinoma.](10.1177_1849454418763725-fig1){#fig1-1849454418763725}

DNA extraction {#section4-1849454418763725}
--------------

Three different types of DNA were obtained from this present patient, including peripheral blood leukocytes, FFPE thyroid tumor tissue, and cfDNA. Total amount of DNA were extracted according to the manufacturer's instructions using QIAamp DNA Blood Mini Kit (cat\# 51106), QIAamp DNA FFPE Tissue Kit (cat\# 56404), and cfDNA QIAamp circulating Nucleic Acid Kit (cat\# 5514), respectively. DNA concentrations were 81 ng/μl, 85 ng/μl, and 81 ng/μl, respectively, and the optical density 260/280 is 1.86, 1.87, and 1.89, respectively. DNA samples were then subjected to Agilent 2100 for more accurate tests. All three DNA samples passed a strict quality test.

Whole exome sequencing {#section5-1849454418763725}
----------------------

The three different samples above were proceeded with WES. Briefly, first, DNA libraries were established with Agilent SureSelect Human All ExonV5 kits, covering about 23,000 genes. After the quality test, qualified libraries were sequenced as 100-bp paired-end reads on Illumina HiSeq 2000 platform (Illumina, San Diego, California, USA) according to the manufacturer's instruction. All of the experiments were carried out in Zhangjiang Center for Translational Medicine, Shanghai, China.

Data analysis {#section6-1849454418763725}
-------------

Clean data were achieved using FastQC and low quality reads were filtered. Burrows--Wheeler Alignment (0.7.12) methods were adopted to map the clean reads to reference genome (UCSC hg19). Then, Picard (<http://picard.sourceforge.net/>) and Genome Analysis Toolkit (GATK) methods were used for duplicate removal, local realignment, and base quality recalibration. GATK unified genotyper was used for variants calling.

ANNOVAR (2015-03-22) software was used to annotate variants for function (exonic, TR, intronic) reference gene, exonic function (synonymous, nonsynonymous, frameshift, stopgain, unknown), amino acid change, allele frequency (AF) 1000 Genomes Project, and dbSNP reference number.

Somatic mutations were analyzed by subtracting the variants of the peripheral blood DNA from the tumor DNA or cfDNA. *T*-test was used to compare the AF between different types of samples. Pearson correlation coefficient was adopted to calculate the relationship between different types of samples.

Results {#section7-1849454418763725}
=======

Exome sequencing, sequence alignment, and variant calling {#section8-1849454418763725}
---------------------------------------------------------

In this study, we totally sequenced three different types of DNAs from one patient. More than 10 Gb sequencing data were generated per sample. The average sequencing depth for peripheral blood DNA, tissue DNA, and cfDNA is 139×, 140×, and 133×, respectively. For three samples, more than 98.7% of the exome was covered at least 10×. The coverage rate for the above three samples was larger than 99.6%. More details are shown in [Table 1](#table1-1849454418763725){ref-type="table"}. The mutation types in different samples were nearly the same.

###### 

Outline of the WES of cfDNA, tumor DNA, and peripheral blood DNA.

![](10.1177_1849454418763725-table1)

                                       Peripheral blood DNA   Tumor DNA   cfDNA
  ------------------------------------ ---------------------- ----------- --------
  Total effective sequence data (Gb)   11.0                   10.0        11.2
  Coverage rate on targeted region     99.76                  99.67       99.8
  Mean depth                           140.04                 139.59      133.21
  No. of SNVs                          41,410                 41,874      41,206
  No. of Indels                        3259                   3490        3486

cfDNA: cell-free DNA; WES: whole exome sequencing.

Variations identified in different samples {#section9-1849454418763725}
------------------------------------------

We compared variations (both SNV and Indel) in different DNA samples. Generally, a large concordance between the three types of samples was observed ([Figure 2(a)](#fig2-1849454418763725){ref-type="fig"}). There were 13,519 common variants in both tissue DNA and cfDNA. They shared more than 98.6% common variants compared with peripheral blood sample. The coefficient rate was 0.95 (*p* value \< 10^−15^) and 0.96 (*p* value \< 10^−15^), respectively; 1.39% of variants identified in tissue DNA were not found in peripheral blood and 1.13% of variants identified in cfDNA did not exist in peripheral blood. Comparing tissue DNA with cfDNA showed that 99.2% variants were identical ([Figure 2(b) to (d)](#fig2-1849454418763725){ref-type="fig"}). The Pearson coefficient between cfDNA and tissue DNA is 0.95 ([Figure 2(e)](#fig2-1849454418763725){ref-type="fig"}).

![Relationship between the three types of DNA samples. (a) Mutation types of three different DNA samples; (b) and (c) common variants are shown by venny diagram; (d) percentages of common or different variants shown in histogram (green, common variants; red, different variants); (e) correlation among variants in different samples.](10.1177_1849454418763725-fig2){#fig2-1849454418763725}

Somatic mutations were determined by subtracting the variants of the peripheral blood leukocytes DNA from the tumor DNA or cfDNA. Fifty-five somatic mutations were found in tissue DNA, in which 5 mutations were nonsynonymous. Seventy-two somatic mutations were found in cfDNA, in which 2 of them changed amino acid. Sixteen common alterations existed in both samples, that is, 31.3% in all the tissue somatic mutations ([Table 2](#table2-1849454418763725){ref-type="table"}). Most of the common mutations were synonymous. In cfDNA,only GLUD2 (c.G103A: p.G35R) and HLA-B (c.A652G: p.I218 V) were nonsynonymous mutations, of which GLUD2 (c.G103A: p.G35R) was also found in the tumor DNA.

###### 

List of genes with somatic mutations in tumor and cfDNA.

![](10.1177_1849454418763725-table2)

  Tissue somatic mutation genes   cfDNA somatic mutation genes   Intersection (31%)                    
  ------------------------------- ------------------------------ -------------------- ---------------- --------------
  FAM69A                          UBE2L3                         TTC39A               CILP2            FAM69A
  RPL5                            TFAP2E                         FAM69A               ZNF431           RPL5
  ANKRD45                         FBXO28                         RPL5                 DEFB124          ANKRD45
  SLC9A2                          RHOA                           TMEM56               LOC101927631     RAPGEF4-AS1
  RAPGEF4-AS1                     LOC101243545                   ANKRD45              UBE2L3           EOMES
  ATF2                            TAPT1-AS1                      NUCKS1               FAM9B            TWF2
  EOMES                           BRD9                           DIEXF                SH3KBP1          NCALD
  TWF2                            NEUROD6                        CNRIP1               EFNB1            MPV17L
  RUVBL1                          TMEM229A                       ERMN                 PJA1             UBE2L3
  TM4SF19-AS1                     Unc5D                          RAPGEF4-AS1          MOSPD1           Unc5D
  MARCH6                          DPY19L4                        EOMES                MIR4424          FJX1
  KCTD20                          GLIPR2                         TWF2                 MAP6D1           SNX20
  TMEM248                         HRAS                           GOLIM4               HLA-B            CDRT15L2
  DNAJC2                          FJX1                           HES1                 HLA-DRB1         LOC100287072
  NCALD                           FAM86C1                        PDCL2                PPIA             EID2
  HAS2-AS1                        RCOR1                          ANXA5                NCF1C            GLUD2
  RAB1B                           PDCD7                          CPE                  Unc5D            
  CXCR5                           CHRNA5                         NUDCD2               FAM35BP          
  LNX2                            SNX20                          CASC15               FAM35DP          
  CTAGE10P                        ALOX15P1                       EPB41L2              FJX1             
  EMC7                            CDRT15L2                       FZD1                 LOC338797        
  SNN                             LOC100287072                   XPO7                 SLITRK1          
  MPV17L                          VAT1                           NCALD                MIR4511          
  DCXR                            EID2                           MSANTD3-TMEFF1       IDH3A            
  RWDD2B                          NCOA3                          TMEFF1               GNPTG            
  GLUD2                                                          CSGALNACT2           SNX20            
                                                                 AMBRA1               PAFAH1B1         
                                                                 NAALAD2              CDRT15L2         
                                                                 FGFR1OP2             LOC100287072     
                                                                 MICU2                CERS1            
                                                                 MEIS2                GDF1             
                                                                 MPV17L               EID2             
                                                                 ZNF771               GNG8             
                                                                 TOM1L2               ZNF816-ZNF321P   
                                                                 SMARCE1              GLUD2            

cfDNA: cell-free DNA.

Discussion {#section10-1849454418763725}
==========

Genome-wide sequencing of plasma DNA was first used in prenatal diagnostics, demonstrating comprehensive genome characteristics.^[@bibr6-1849454418763725]^ Recent studies showed that sequencing of circulating cfDNA from plasma is a potential tool for monitoring advanced cancer. Compared with traditional biopsy, cfDNA sequencing is noninvasive, easy to get samples repeatedly, and to large extent reflects the comprehensive genomic characteristic of the tumor progress.^[@bibr2-1849454418763725][@bibr3-1849454418763725]--[@bibr4-1849454418763725],[@bibr7-1849454418763725]^ In our data, cfDNA from FTC was for the first time sequenced together with primary tumor in the advanced thyroid cancer. The results demonstrate that SNV and mutation rate of cfDNA are characterized by the features of FTC, and both tissue DNA and cfDNA shared more than 95% common alterations. It will be helpful for doctors or researchers to use cfDNA as a new method for the diagnosis and monitoring of thyroid carcinoma.

Recent studies showed that cancers arise through a process of somatic evolution that can result in substantial sub-clonal heterogeneity within tumors, and a large fraction of polyclonal tumors and a larger sub-clonal mutation fraction may be associated with relapse and metastasis.^[@bibr8-1849454418763725],[@bibr9-1849454418763725]^ It has been established that there were different mutation variants between primary and metastatic tumors. In our results, there were different variants identified in tissue DNA and cfDNA except for common alterations. One of the reasons may be the existence of distinct mutational genes of bone and lung metastatic tumors in cfDNA.^[@bibr7-1849454418763725]^ In addition, the detection of genomic alteration by sequencing of cfDNA is to some extent dependent on the AF of the mutant alleles in the tissue DNA. AF value of variants which existed in both cfDNA and tissue DNA is significantly larger than that of variants only existed in tissue DNA, indicating that the higher the AF is in tissue DNA, the easier the cfDNA is to be detected. Thirdly, the sensitivity of cfDNA sequencing was dependent on sequencing depth.^[@bibr10-1849454418763725]^ High sequencing depth will help to find rare mutations in tissue DNA. In this study, we acquired 100 sequencing depth, so the mutation with less than 1% AF is unable to be identified theoretically.

Except for FAM69A, RAPGEF4-AS1, LOC100287072, and CDRT15L2, most of these common mutation genes are related to many functions of cancer cells, and Unc5D gene inhibits thyroid cancer cell behaviors.^[@bibr11-1849454418763725]^ As a common nonsynonymous mutant gene GLUD2, its activity supports cancer cell proliferation under glutamine depletion.^[@bibr12-1849454418763725]^ Therefore, these gene mutations may be involved in the metastatic process of FTC.

In summary, we first performed WES from cfDNA of an advanced thyroid cancer patient. This pilot study provided preliminary evidence that cfDNA represents the genomic characteristics of primary FTC, implying the risk of metastasis. Further studies guarantee sequencing of metastatic tumors, increase more cases, and determine the biomarker of cfDNA for metastasis of thyroid cancer.
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